{"transactions":[{"id":955356,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":70611,"kind":"person","name":"DiRaimondo Thomas","position":1,"cik":"0002005618","reported_name":"DiRaimondo Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock option (right to buy)","published_at":"2026-01-02T21:00:15.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":109900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares subject to the option vest on January 1, 2027 and the balance will vest in equal monthly installments thereafter over a three year period."}],"balance_after":109900,"derivative":{"exercise_price":13.65,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":109900},"source":{"system":"sec-edgar","filing":"0002005618-26-000002","document":"form4-01022026_090110.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2005618/000200561826000002/form4-01022026_090110.xml","form_type":"4"}},{"id":955355,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":70611,"kind":"person","name":"DiRaimondo Thomas","position":1,"cik":"0002005618","reported_name":"DiRaimondo Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-01-02T21:00:15.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":31400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the grant of restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments beginning on January 1, 2027."}],"balance_after":155825,"source":{"system":"sec-edgar","filing":"0002005618-26-000002","document":"form4-01022026_090110.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2005618/000200561826000002/form4-01022026_090110.xml","form_type":"4"}},{"id":955354,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":70611,"kind":"person","name":"DiRaimondo Thomas","position":1,"cik":"0002005618","reported_name":"DiRaimondo Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-01-02T21:00:15.000Z","date":"2026-01-02","kind":"sale","planned":false,"acquired":false,"shares":2505,"price":13.73,"value":34393.65,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were automatically sold to cover tax withholding obligations associated with the vesting of restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 4,049 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan (the \"Plan\") on May 15, 2025. Also, on January 3, 2025, the Reporting Person filed a Form 4 which inadvertently reported an aggregate of 7,781 shares acquired under the Plan.  In fact, 5,432 of the shares were already reported as acquired by the Reporting Person under the Plan on a Form 3 filed on January 3, 2024 and 1,406 of the shares were reported as acquired by the Reporting Person under the Plan on a Form 4 filed on September 27, 2024."}],"balance_after":124425,"source":{"system":"sec-edgar","filing":"0002005618-26-000002","document":"form4-01022026_090110.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2005618/000200561826000002/form4-01022026_090110.xml","form_type":"4"}},{"id":1315539,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":70611,"kind":"person","name":"DiRaimondo Thomas","position":1,"cik":"0002005618","reported_name":"DiRaimondo Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock option (right to buy)","published_at":"2025-01-03T20:10:06.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":84000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to the option vest on January 1, 2026 and the balance will vest in equal monthly installments thereafter over a three year period."}],"balance_after":84000,"derivative":{"exercise_price":53.24,"expiration_date":"2035-01-01","underlying":"Common Stock","underlying_shares":84000},"source":{"system":"sec-edgar","filing":"0001415889-25-000673","document":"form4-01032025_080103.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2005618/000141588925000673/form4-01032025_080103.xml","form_type":"4"}},{"id":1315538,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":70611,"kind":"person","name":"DiRaimondo Thomas","position":1,"cik":"0002005618","reported_name":"DiRaimondo Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-01-03T20:10:06.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments beginning on January 1, 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 497 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan (the \"Plan\") on November 15, 2021, 1,327 shares acquired under the Plan on May 13, 2022, 1,130 shares acquired under the Plan on November 15, 2022, 1,715 shares acquired under the Plan on May 15, 2023, 763 share acquired under the Plan on November 15, 2023, 1,406 shares acquired under the Plan on May 15, 2024 and 943 shares acquired under the Plan on November 15, 2024."}],"balance_after":129719,"source":{"system":"sec-edgar","filing":"0001415889-25-000673","document":"form4-01032025_080103.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2005618/000141588925000673/form4-01032025_080103.xml","form_type":"4"}},{"id":1398554,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":70611,"kind":"person","name":"DiRaimondo Thomas","position":1,"cik":"0002005618","reported_name":"DiRaimondo Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-09-27T19:31:52.000Z","date":"2024-09-27","kind":"sale","planned":true,"acquired":false,"shares":675,"price":47.2245,"value":31876.5375,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The weighted average sale price for the transaction reported was $47.2245 and the range of prices were between $46.79 and $47.77.  Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":97938,"source":{"system":"sec-edgar","filing":"0001415889-24-024076","document":"form4-09272024_110948.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2005618/000141588924024076/form4-09272024_110948.xml","form_type":"4"}},{"id":1398553,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":70611,"kind":"person","name":"DiRaimondo Thomas","position":1,"cik":"0002005618","reported_name":"DiRaimondo Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-09-27T19:31:52.000Z","date":"2024-09-27","kind":"sale","planned":true,"acquired":false,"shares":4325,"price":46.2057,"value":199839.6525,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $46.2057 and the range of prices were between $45.70 and $46.69. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 1,406 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan on May 15, 2024."}],"balance_after":98613,"source":{"system":"sec-edgar","filing":"0001415889-24-024076","document":"form4-09272024_110948.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2005618/000141588924024076/form4-09272024_110948.xml","form_type":"4"}},{"id":1693466,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":70611,"kind":"person","name":"DiRaimondo Thomas","position":1,"cik":"0002005618","reported_name":"DiRaimondo Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-01-03T16:47:56.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":147000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vest on January 1, 2025 and the balance will vest in equal monthly installments thereafter over a three year period."}],"balance_after":147000,"derivative":{"exercise_price":11.02,"expiration_date":"2034-01-01","underlying":"Common Stock","underlying_shares":147000},"source":{"system":"sec-edgar","filing":"0001209191-24-000426","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2005618/000120919124000426/doc4.xml","form_type":"4"}}]}